Highlights Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 04:00:02 2024-04-30 pm EDT			5-day change	1st Jan Change
18.61 ^USD	-1.53%		+0.49%	+29.06%

Apr. 29	Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating	MT
Apr. 09	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	Mar. 19	MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	Feb. 15	MT
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	Feb. 15	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83	Feb. 15	MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	Feb. 15	CI
Organon & Co. Provides Earnings Guidance for the Year 2024	Feb. 15	CI
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	Jan. 10	CI
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump	Jan. 08	MT
Organon Signs Agreement With Eli Lilly to Distribute, Market Two Migraine Medicines in Europe	Dec. 18	MT
Organon & Co. and Eli Lilly and Company Enter Commercialization Agreement in Europe for Two Migraine Medicines	Dec. 18	CI
China health sector sees better sentiment from anti-graft drive - execs	Nov. 09	RE
Lupin Launches Rocuronium Bromide Injection	Nov. 08	MT
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application for Interchangeability Designation for HADLIMA? (Adalimumab-bwwd)	Nov. 07	CI
Organon & Co. Revises Earnings Guidance for 2023	Nov. 02	CI
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023	Nov. 02	CI
Earnings Flash (OGN) ORGANON & CO. Reports Q3 Revenue $1.52B, vs. Street Est of $1.57B	Nov. 02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Organon & Co.

Equities

OGN

US68622V1061

Highlights

Filters